

Fax completed form to: 1-866-868-0858  
Questions, please call: 1-866-316-6049



## **Important Information About Prescription Drug Coverage**

---

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Valcyte® (valganciclovir): Prior Authorization Request Form: Please respond.

---

- Please complete the attached Valcyte® (valganciclovir) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

---

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

# Prior Authorization Request Form



Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
Member ID \_\_\_\_\_  
Medicare ID \_\_\_\_\_  
Date of birth \_\_\_\_\_ Sex: M / F  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_  
Nursing home resident? YES / NO  
Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
Specialty \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Pharmacy name \_\_\_\_\_  
NCPDP \_\_\_\_\_  
NPI \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Valcyte® (valganciclovir) Criteria

- Please indicate the patient's diagnosis. Select or indicate the correct ICD-9 code. This question must be completed.  
 AIDS- Cytomegaloviral retinitis in patients with AIDS. (ICD-9: 078.5)  
 Prophylaxis of Cytomegalovirus infection, in high risk kidney, heart, and kidney-pancreas transplant patients who are high risk (Donor CMV seropositive/Recipient CMV seronegative [(D+/R-)]) (V42, 078.5)  
 Other (diagnosis and ICD-9 code): \_\_\_\_\_
- Is the prescribing physician an ophthalmologist, transplant surgeon, infectious disease specialist or has one been consulted?  
 Yes  No
- Does the patient have any of the following contraindications to Valcyte® (e.g., hypersensitivity to valganciclovir or ganciclovir, absolute neutrophil count is less than 500 cells/microliter, platelet count is less than 25,000/microliter, hemoglobin less than 8 g/dL, or on hemodialysis)?  
 Yes  No
- If the patient's diagnosis is CMV retinitis, have they failed to receive a clinically appropriate therapeutic response OR demonstrated intolerance (e.g., allergy, hypersensitivity, adverse effects(s), development of a contraindication) from either intravenous ganciclovir, ganciclovir ocular implant (Vitrasert®), intravenous foscarnet or oral ganciclovir?  
 Yes  No  Not applicable
- If the patient's diagnosis is prophylaxis of CMV infection in high risk kidney, heart or kidney-pancreas transplant patients, have they failed to receive a clinically appropriate therapeutic response OR demonstrated intolerance (e.g., allergy, hypersensitivity, adverse effects(s), development of a contraindication) from ganciclovir?  
 Yes  No  Not applicable

Medical Justification: (Attach additional page if necessary): \_\_\_\_\_  
\_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_